The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.75
Bid: 41.00
Ask: 42.50
Change: 5.25 (14.38%)
Spread: 1.50 (3.659%)
Open: 37.00
High: 42.50
Low: 36.00
Prev. Close: 36.50
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Northamber loss widens; Ethernity contract boost

Thu, 28th Mar 2024 13:44

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

----------

Northamber PLC - London-based distributor of audio-visual and information technology equipment - Revenue in the six months to December 31 falls to GBP29.2 million from GBP33.6 million while pretax loss widens to GBP413,000 from GBP250,000. Notes broader macro-economic factors and market sentiment impacted the industry. Explains softer demand resulted in slower stock turns, leading to an increase in stock at period end of GBP10.3 million compared to GBP9.6 million. Proposes unchanged interim dividend of 0.3p. Remains cautious short term as the UK market continues to be challenging but notes industry analysts expect a recovery through 2024 in demand levels as business confidence hopefully returns.

----------

Ethernity Networks Ltd - Israel-based supplier of data processing semiconductor technology for networking appliances - Announces business update. Highlights positive engagement with a number of potential new customers, including two OEM vendors which, following an extensive evaluation of Ethernity's Universal Edge Platform have indicated an interest to adopt and launch the product to their customer base. Talks continue with these two vendors on potential contracts that could lead to significant business for Ethernity. Estimates the contracts could contribute between USD2.2 million and USD3 million to revenue in 2024, plus "significantly higher revenues in 2025 and beyond".

----------

Rurelec PLC - gas producer focused on operations in Latin America - Reports pretax profit in the six months to December 31 of GBP559,000, swinging from pretax loss of GBP2.9 million. Earnings per share total 0.09 pence compared to LPS of 0.51p. Administration expenses decline to GBP0.31 million from GBP0.48 million. Explains the board's strategy is now to seek a reverse takeover "through which to generate value for our shareholders, and to give the company access to further resource thereby allowing more time to achieve a sale of the two Siemens 701 turbines." Adds: "While we continue to hold discussions with credible potential purchasers of the turbines, these initiatives are at an early stage following the withdrawal of counterparties to our earlier discussions for reasons unconnected with Rurelec. The timing of any potential sale of the turbines remains highly uncertain owing to the limited demand and infrequent occurrence of projects into which the turbines could be injected."

----------

Sareum Holdings PLC - Reports pretax loss in the six months to December 31 widens to GBP3.3 million from GBP1.7 million. No revenue was disclosed as per the year prior. Operating expenses rise to GBP2.5 million from GBP1.7 million. Basic and diluted loss per share totals 3.6 pence compared to 2.1p. Further, raises GBP1.5 million via placing, subscription and retail offer at 10p per share. Intends to use proceeds to complete Phase 1a clinical studies on its SDC-1801 TYK2/JAK1 inhibitor and, together with the receipt of an anticipated R&D tax credit of GBP0.7 million for general working capital purposes.

----------

Team PLC - wealth, asset management and complementary financial services group - Plans to raise GBP1.1 million via GBP700,000 placing and GBP400,000 subscription at 20 pence per share. Explains funds will be used for the financing of acquisitions and deferred consideration, as well as providing cash for working capital and general corporate purposes. Notes fundraise is supported by existing and new shareholders. Further, intends to raise GBP750,000 via retail offer.

----------

First Tin PLC - London-based tin development company focused on advanced, low-capital expenditure projects in Germany and Australia - Reports pretax loss in 2023 narrows to GBP2.3 million from GBP3.2 million the year prior. Diluted loss per share totals 0.85 pence compared to 1.40p. Says 2024 is shaping up to be "another busy year" with the definitive feasibility study at the Taronga asset soon to be completed and the finalisation of the mineral resource estimate at the Tellerhauser asset in the third quarter. "Our outlook for the tin market remains bullish, and we are already seeing strong signs of tin price recovery. The demand for tin remains ever-present as tin becomes increasingly recognised as crucial to the global energy transition and digital revolution," company states.

----------

Home REIT PLC - London-based real estate company, which focuses on investing in accommodation for homeless people - Sells 63 properties for GBP6.1 million, around 1.8% of the company's portfolio by value. Notes gross proceeds from the sales are GBP0.5 million, below the draft August 2023 values. Explains the majority of the properties sold are below portfolio average lot size which may cause a greater percentage variation when comparing sale price to the August draft valuation. Since August 2023, the company has completed on the sale of 451 properties and exchanged on a further 257 properties. Sale proceeds will be used to reduce borrowings and provide working capital.

----------

React Group PLC - Birmingham, England-based cleaning, hygiene and decontamination firm - Issues trading statement ahead of Thursday's annual general meeting. Reports that revenue for the first five months of the current financial year ending September is ahead of the same period in last year. Says: "Each division has performed well and the group continues to benefit from cross selling opportunities which not only enhance our offering but also contribute to the organic growth. It is particularly pleasing to deliver revenue growth in a challenging market environment where our customers are always striving for the best in class service that we offer."

----------

Westminster Group PLC - London-based provider of security services, for sensitive places such as ports, airports and commercial buildings - Revenue in the six months to December 31 falls to GBP2.9 million from GBP3.5 million the year before, while pretax loss widens to GBP1.9 million from GBP287,000. Loss per share totals 0.58 pence compared to 0.09p. Chief Executive Peter Fowler says: "We continue to battle against probably one of the worst world economic and political backgrounds in recent times." Explains revenue fell largely due to the economic climate delaying some capital-intensive orders. Fowler adds: "We started 2024 with an order book of GBP1.1 million and recurring revenues of GBP3.7 million which provide a healthy start for the year. With DRC expected to come on stream and other potential projects in the pipeline we believe the months and year ahead will be transformative for the group."

----------

By Jeremy Cutler, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
13 Jun 2019 15:49

Sareum Plans To Start Human Trials Of Two Drug Candidates In 2020

(Alliance News) - Sareum Holdings PLC on Thursday said it has been focusing on toxicology studies in its development of drug candidates SDC-1801 and SDC-1802 with a view to CONDUCT human trials in

Read more
3 Jun 2019 17:38

Sareum Notes Sierra Oncology's Positive Preliminary Results Of SRA737

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it noted its licensee Sierra Oncology's webcast discussing clinical findings and possible next steps for SRA737, its oral checkpoint

Read more
3 Jun 2019 10:02

Sareum Reports Positive Data From Trials Of SRA737 In Advanced Cancer

LONDON (Alliance News) - Sareum Holdings PLC on Monday said that Sierra Oncology reported positive preliminary clinical data from two in-human studies of SRA737.Shares in the drug company a

Read more
4 Mar 2019 10:58

Sareum Interim Loss Deepens On Costs As Pipeline Continues Progress

LONDON (Alliance News) - Cancer drug discovery firm Sareum Holdings PLC said Monday its interim loss widened as costs rose, but it made progress with its key developmental programmes.For to

Read more
4 Mar 2019 08:26

Sareum's loss widens as development costs expand

(Sharecast News) - Sareum Holdings' shares dropped on Monday after the company reported a widened interim loss due to rising costs, though it stated progress had been made with key development programmes.

Read more
28 Feb 2019 14:33

Sareum flags potentially significant findings for SRA737

(Sharecast News) - Specialist small molecule drug development company Sareum Holdings announced on Thursday that Sierra Oncology, the licence holder advancing clinical cancer candidate SRA737, had reported that an abstract reporting preclinical data for SRA737 - its Chk1 inhibitor - plus low dose gemcitabine (LDG), in combination with immunotherapy, had been selected for a late-breaking oral presentation at the American Association of Cancer Research annual meeting.

Read more
11 Dec 2018 15:55

UK Shareholder Meetings Calendar - Next 7 Days

Wednesday 12 DecemberBlancco Technology GroupBellwayVolution Shopping REIT (re voluntary 13 Asian 14 to

Read more
30 Nov 2018 11:48

Sareum Reports Efficacy Data For Immunotherapy Combination With SRA737

LONDON (Alliance News) - Sareum Holdings PLC said Friday that Sierra Oncology Inc reported preclinical efficacy data for an immunotherapy combination with its SRA737 inhibitor in lung licences the

Read more
26 Oct 2018 09:20

Sareum Holdings Raises GBP850,000 Via Share Placing (ALLISS)

LONDON (Alliance News) - Sareum Holdings PLC said Friday it raised GBP850,000 via the issue of 130.8 million shares to fund the development of its lead cancer and autoimmune drugs.The drug

Read more
26 Oct 2018 08:38

Sareum raises £850,000 to fund cancer inhibitor

(Sharecast News) - Drug maker Sareum has raised £850,000 to progress the development programme of its cancer inhibitor TYK2/JAK1.

Read more
1 Oct 2018 11:30

Sareum Swings To Annual Loss After Prior Year Profit From Associates

LONDON (Alliance News) - Sareum Holdings PLC on Monday said it swung to an annual loss after reporting a substantial share of profit from associates the year before.Shares in Sareum were at

Read more
26 Sep 2018 15:20

Sareum Holdings selects cancer therapy development candidate

(Sharecast News) - Drug discovery and development company Sareum Holdings has made the formal selection of a development candidate from its TYK2 inhibitor programme to advance through preclinical development as a potential new targeted therapy for certain cancers, it announced on Wednesday.

Read more
26 Sep 2018 14:05

Sareum Selects Candidate To Develop Cancer Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Wednesday that it has selected the SDC-1802 molecule from the TYK2 inhibitor programme for further development as potential treatment for certain

Read more
11 Sep 2018 13:28

Sareum Holdings Expects To Swing To GBP1.5 Million Annual Loss

LONDON (Alliance News) - Sareum Holdings PLC said Tuesday it expects to report a loss in its annual results as it progresses on its programmes in autoimmune diseases and cancer.The drug it

Read more
10 Sep 2018 11:52

Sareum Picks SDC-1801 For Development As Autoimmune Disease Treatment

LONDON (Alliance News) - Sareum Holdings PLC said Monday it will develop SDC-1801 as a possible treatment for autoimmune diseases.The molecule, SDC-1801, has been formally selected for is a

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.